ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / QUCY / news
SDEV (33) TENX (27) TELO (28) MAIA (32) ⌘ Pro Terminal →

Why QUCY Stock dropped -4.67% Today — RQD Quant Desk Flash

$0.72 -4.67% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.71

Quantum Cyber N.V. (QUCY) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $66.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on QUCY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is QUCY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Quantum Cyber N.V. (NASDAQ: QUCY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $0.72 (-4.67% 1D, market cap $66.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, QUCY ranks #864 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does QUCY compare to SDEV and TENX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QUCY carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 72.6%, and ROIC of -35.0%. By comparison, SDEV (Stablecoin Development Corporation) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $67.3M) and TENX (Tenax Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $67.4M). Among the 5-stock peer group, QUCY leads on earnings multiple (N/A) while QUCY leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for QUCY?
▼

Per QUCY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001874252), Quantum Cyber N.V. generated $537.1K in revenue (-39.9% YoY), -$16.2M in net income, and -$11.0M in free cash flow against $5.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.71 (-1.03%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510028
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (8)Whales (3)SEC (8)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.9% Base Target
$5 Bull$1 Base$0 Bear
📬 FREE QUCY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QUCY)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
🔍 WHY QUCY SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (29% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 39% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$1.03-1% Next Q
Q2 (-2Q)
33
Grade E$1.02-5.9% Next Q
Q3 (-1Q)
31
Grade E$0.96-25% Next Q
Current
28
Grade E$0.72-10% Hist 90D α
Trajectory: E (36) → E (28)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a QUCY Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While QUCY currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.23) and Max Pain ($0.76) forces dealer call-delta covering toward $5.18.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $QUCY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “QUCY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 28%NO 72%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why QUCY Stock dropped -4.67% Today — RQD Quant Desk Flash

Quantum Cyber N.V. (QUCY) dropped -4.67% to $0.72, trading at 9% of its 52-week range ($0.3 – $4.93). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 9% of its 52-week range ($0.3 – $4.93) with RSI-14 at 30.6 (OVERSOLD (<32)).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.72 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 39% gross margin and $0 annual free cash flow.
Live QUCY Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QUCY)

  • ✓Walkthrough of QUCY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
QUCY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +100.00%▼ SUPPORT BREAKDOWN
2026-11-04O $0.84H $0.84L $0.72C $0.72VOL 321.7K
RES: $1.43SUP: $0.86SMA50: $1.23SMA200: $1.20
$5.25$3.91$2.57$1.23$-0.12RES $1.43SUP $0.86$0.722026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QUCY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 QUCY Butterfly Map → + Track QUCY →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -39.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on QUCY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for QUCY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for QUCY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QUCY)

Health Care Rank #864 of 1015 ⚔️ SDEV vs QUCY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (QUCY vs. SDEV, TENX, TELO, MAIA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Quantum Cyber N.V. (QUCY) ranks #864 by composite RQD confidence (28/100, grade E) and #705 by equity capitalization ($66.2M). Within this direct 5-issuer industry benchmark cohort, QUCY leads on earnings valuation at N/A trailing P/E, while QUCY leads on capital efficiency and profitability with -35.0% ROIC and 72.6% gross margin. SDEV currently holds the highest overall quantitative score in the immediate peer group at 33/100 (E) compared with QUCY at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
QUCY ACTIVE
Quantum Cyber N.V.
E 28/100 — 72.6% -35.0% -4.67% $66.2M Benchmark Subject
SDEV
Stablecoin Development Corporation
E 33/100 — — -35.0% +3.26% $67.3M /sdev-vs-qucy →
TENX
Tenax Therapeutics Inc.
E 27/100 — — -35.0% +2.22% $67.4M /tenx-vs-qucy →
TELO
Telomir Pharmaceuticals Inc.
E 28/100 — — -35.0% -0.56% $67.4M /telo-vs-qucy →
MAIA
MAIA Biotechnology Inc.
E 32/100 — — -35.0% -1.82% $67.9M /maia-vs-qucy →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001874252 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Quantum Cyber N.V. (QUCY) reported GAAP revenue of $537.1K (-39.9% vs. FY2024 revenue of $894.0K ) , GAAP net income of -$16.2M, operating cash flow of -$11.0M, and free cash flow of -$11.0M (+37.0% YoY). On the balance sheet, QUCY closed FY2025 with $5.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $537.1K -$16.2M -$11.0M -$11.0M $5.3M —
FY2024 (FY) 2024-12-31 $894.0K -$21.6M -$17.3M -$17.4M $13.5M —

3. QUCY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QUCY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Quantum Cyber N.V. (NASDAQ: QUCY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $0.72 (-4.67% 1D, market cap $66.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, QUCY ranks #864 in composite RQD confidence.

How does QUCY compare to SDEV and TENX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QUCY carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 72.6%, and ROIC of -35.0%. By comparison, SDEV (Stablecoin Development Corporation) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $67.3M) and TENX (Tenax Therapeutics Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $67.4M). Among the 5-stock peer group, QUCY leads on earnings multiple (N/A) while QUCY leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for QUCY?

Per QUCY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001874252), Quantum Cyber N.V. generated $537.1K in revenue (-39.9% YoY), -$16.2M in net income, and -$11.0M in free cash flow against $5.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is QUCY trading relative to its 50-day, 200-day, and 52-week technical levels?

QUCY last traded at $0.72 (-4.67% on volume of 313,659 shares), positioning the stock -41.46% below its 50-day simple moving average ($1.23) and -40.00% below its 200-day simple moving average ($1.20). Across its 52-week range of $0.30 to $4.93, QUCY sits at the 9.1% percentile with a 14-day RSI of 30.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.81).

Direct Sub-Reports: QUCY RQD Cockpit QUCY 12M Forecast QUCY Earnings & Move QUCY Dividends & DRIP QUCY Insiders & 13F QUCY Whale Options QUCY Profit Sankey QUCY News & Why
ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ SEC XBRL & RQD VERIFIED

QUCY — Quantum Cyber N.V.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Quantum Cyber N.V. (QUCY) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.72 (-4.67% 1D, market capitalization $66.2M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 72.6%, operating margin of -60.0%, and free cash flow yield of -13.84%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

.V. (QUCY) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The source data reports FY 2025 revenue of $0.5M indicating minimal top-line scale.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Quantum Cyber N.V. (QUCY) reported $537.1K in annual revenue (up from $894.0K in FY2024, -39.9% YoY) and -$16.2M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($894.0K revenue, -$21.6M net income) through FY2025, QUCY scaled operating cash flow to -$11.0M and free cash flow to -$11.0M, backed by $5.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -13.84% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.30 – $4.93 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream or downstream dependencies, sector correlations, or second-order bottlenecks. An investor should note that the absence of mapped links means this analysis cannot identify ripple effects from the source data alone.

  • Key Question #1: Can QUCY sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $537.1K and free cash flow of -$11.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is QUCY's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

QUCY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Quantum Cyber N.V. (QUCY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to QUCY Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

QUCY Bull vs. Bear Conversation Board — What's Your Call at $0.72?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON QUCY 🐻 33% BEARISH CONVICTION
1. Pick Your Side on QUCY:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $1.08 (+28.6%)
📌 Pinned Debate

Net loss narrowed from -$21.6M in FY 2024 to -$16.2M in FY 2025 while the stock trades near the low end of its $0.82–$1.02 52-week rang

The street is overcomplicating Quantum Cyber N.V. (QUCY). Net loss narrowed from -$21.6M in FY 2024 to -$16.2M in FY 2025 while the stock trades near the low end of its $0.82–$1.02 52-week range.. With an RQD score of 28/100 (E) and Forensic Balance Sheet at 8/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $0.91.

ArenaChamp_24 🐂 BULL

@AlphaFlow_Cap Agree on the RQD 28/100 quality, though with 1.0 beta I'm scaling in with half-size at $0.84 and keeping dry powder in case we test $0.78.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $0.71 (-15.5%)
Spot @ $0.84

A $100 Million ATM equity program alongside ROIC of -35% and FCF yield of -13.84% signals ongoing dilution and cash-burn pressure.

Sitting on the sidelines or leaning short QUCY above $0.84. A $100 Million ATM equity program alongside ROIC of -35% and FCF yield of -13.84% signals ongoing dilution and cash-burn pressure.. Until Fundamental Cash Engine (8/20) and FCF yield (-13.84%) inflect higher, upside is capped near $4.93.

LIVE TAPE